Bayer Bigs Up Vitrakvi In Comparison With Roche's Rozlytrek
Two Tumor-Agnostic Therapies In ESMO Spotlight
Executive Summary
In the absence of head-to-head data, the results from a "matching-adjusted indirect comparison" suggest favorable efficacy of the German group's treatment for solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion when compared with competitor Rozlytrek from Roche.